Clostridium Diagnostics

Clostridium Diagnostics

Global Clostridium Diagnostics Market to Reach $4.7 Billion by 2027

Amid the COVID-19 crisis, the global market for Clostridium Diagnostics estimated at US$1.9 Billion in the year 2020, is projected to reach a revised size of US$4.7 Billion by 2027, growing at aCAGR of 13.9% over the period 2020-2027. Immunoassays, one of the segments analyzed in the report, is projected to record 15.4% CAGR and reach US$3.7 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Molecular Diagnostics segment is readjusted to a revised 9.5% CAGR for the next 7-year period.

The U.S. Market is Estimated at $512.3 Million, While China is Forecast to Grow at 18.4% CAGR

The Clostridium Diagnostics market in the U.S. is estimated at US$512.3 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.1 Billion by the year 2027 trailing a CAGR of 18.4% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 9.6% and 12.2% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 10.9% CAGR.

Select Competitors (Total 42 Featured) -

  • Abbott Laboratories
  • Beckman Coulter, Inc.
  • Becton, Dickinson & Company
  • bioMerieux SA
  • Chrono-log Corporation
  • Corgenix
  • Diazyme Laboratories
  • F. Hoffmann-La Roche AG
  • Fujirebio US, Inc.
  • Hologic, Inc.
  • QIAGEN GmbH
  • Siemens Healthineers
  • Sysmex Corporation
  • Thermo Fisher Scientific, Inc.
Please note: Reports are sold as single-site single-user licenses. The delivery time for hard copies is between 3-5 business days, as each hard copy is custom printed for the organization ordering it. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.


I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Impact of Covid-19 and a Looming Global Recession
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS
3.
MARKET TRENDS & DRIVERS DRIVERS
4.
GLOBAL MARKET PERSPECTIVE
TABLE 1: World Current & Future Analysis for Clostridium Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
TABLE 2: World Historic Review for Clostridium Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 3: World 15-Year Perspective for Clostridium Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2012, 2020 & 2027
TABLE 4: World Current & Future Analysis for Immunoassays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
TABLE 5: World Historic Review for Immunoassays by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 6: World 15-Year Perspective for Immunoassays by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
TABLE 7: World Current & Future Analysis for Molecular Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
TABLE 8: World Historic Review for Molecular Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 9: World 15-Year Perspective for Molecular Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
TABLE 10: World Current & Future Analysis for Clostridium difficile by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
TABLE 11: World Historic Review for Clostridium difficile by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 12: World 15-Year Perspective for Clostridium difficile by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
TABLE 13: World Current & Future Analysis for Clostridium perfringens by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
TABLE 14: World Historic Review for Clostridium perfringens by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 15: World 15-Year Perspective for Clostridium perfringens by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
TABLE 16: World Current & Future Analysis for Clostridium botulinum by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
TABLE 17: World Historic Review for Clostridium botulinum by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 18: World 15-Year Perspective for Clostridium botulinum by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
TABLE 19: World Current & Future Analysis for Clostridium tetani by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
TABLE 20: World Historic Review for Clostridium tetani by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 21: World 15-Year Perspective for Clostridium tetani by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
TABLE 22: World Current & Future Analysis for Clostridium sordellii by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
TABLE 23: World Historic Review for Clostridium sordellii by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 24: World 15-Year Perspective for Clostridium sordellii by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
TABLE 25: World Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
TABLE 26: World Historic Review for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 27: World 15-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
TABLE 28: World Current & Future Analysis for Independent Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
TABLE 29: World Historic Review for Independent Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 30: World 15-Year Perspective for Independent Laboratories by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
TABLE 31: World Current & Future Analysis for Physicians Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
TABLE 32: World Historic Review for Physicians Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 33: World 15-Year Perspective for Physicians Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
III. MARKET ANALYSIS
UNITED STATES
TABLE 34: USA Current & Future Analysis for Clostridium Diagnostics by Technology - Immunoassays and Molecular Diagnostics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 35: USA Historic Review for Clostridium Diagnostics by Technology - Immunoassays and Molecular Diagnostics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 36: USA 15-Year Perspective for Clostridium Diagnostics by Technology - Percentage Breakdown of Value Sales for Immunoassays and Molecular Diagnostics for the Years 2012, 2020 & 2027
TABLE 37: USA Current & Future Analysis for Clostridium Diagnostics by Bacterial Strain - Clostridium difficile, Clostridium perfringens, Clostridium botulinum, Clostridium tetani and Clostridium sordellii - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 38: USA Historic Review for Clostridium Diagnostics by Bacterial Strain - Clostridium difficile, Clostridium perfringens, Clostridium botulinum, Clostridium tetani and Clostridium sordellii Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 39: USA 15-Year Perspective for Clostridium Diagnostics by Bacterial Strain - Percentage Breakdown of Value Sales for Clostridium difficile, Clostridium perfringens, Clostridium botulinum, Clostridium tetani and Clostridium sordellii for the Years 2012, 2020 & 2027
TABLE 40: USA Current & Future Analysis for Clostridium Diagnostics by End-Use - Hospitals, Independent Laboratories and Physicians Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 41: USA Historic Review for Clostridium Diagnostics by End-Use - Hospitals, Independent Laboratories and Physicians Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 42: USA 15-Year Perspective for Clostridium Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Independent Laboratories and Physicians Clinics for the Years 2012, 2020 & 2027
CANADA
TABLE 43: Canada Current & Future Analysis for Clostridium Diagnostics by Technology - Immunoassays and Molecular Diagnostics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 44: Canada Historic Review for Clostridium Diagnostics by Technology - Immunoassays and Molecular Diagnostics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 45: Canada 15-Year Perspective for Clostridium Diagnostics by Technology - Percentage Breakdown of Value Sales for Immunoassays and Molecular Diagnostics for the Years 2012, 2020 & 2027
TABLE 46: Canada Current & Future Analysis for Clostridium Diagnostics by Bacterial Strain - Clostridium difficile, Clostridium perfringens, Clostridium botulinum, Clostridium tetani and Clostridium sordellii - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 47: Canada Historic Review for Clostridium Diagnostics by Bacterial Strain - Clostridium difficile, Clostridium perfringens, Clostridium botulinum, Clostridium tetani and Clostridium sordellii Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 48: Canada 15-Year Perspective for Clostridium Diagnostics by Bacterial Strain - Percentage Breakdown of Value Sales for Clostridium difficile, Clostridium perfringens, Clostridium botulinum, Clostridium tetani and Clostridium sordellii for the Years 2012, 2020 & 2027
TABLE 49: Canada Current & Future Analysis for Clostridium Diagnostics by End-Use - Hospitals, Independent Laboratories and Physicians Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 50: Canada Historic Review for Clostridium Diagnostics by End-Use - Hospitals, Independent Laboratories and Physicians Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 51: Canada 15-Year Perspective for Clostridium Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Independent Laboratories and Physicians Clinics for the Years 2012, 2020 & 2027
JAPAN
TABLE 52: Japan Current & Future Analysis for Clostridium Diagnostics by Technology - Immunoassays and Molecular Diagnostics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 53: Japan Historic Review for Clostridium Diagnostics by Technology - Immunoassays and Molecular Diagnostics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 54: Japan 15-Year Perspective for Clostridium Diagnostics by Technology - Percentage Breakdown of Value Sales for Immunoassays and Molecular Diagnostics for the Years 2012, 2020 & 2027
TABLE 55: Japan Current & Future Analysis for Clostridium Diagnostics by Bacterial Strain - Clostridium difficile, Clostridium perfringens, Clostridium botulinum, Clostridium tetani and Clostridium sordellii - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 56: Japan Historic Review for Clostridium Diagnostics by Bacterial Strain - Clostridium difficile, Clostridium perfringens, Clostridium botulinum, Clostridium tetani and Clostridium sordellii Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 57: Japan 15-Year Perspective for Clostridium Diagnostics by Bacterial Strain - Percentage Breakdown of Value Sales for Clostridium difficile, Clostridium perfringens, Clostridium botulinum, Clostridium tetani and Clostridium sordellii for the Years 2012, 2020 & 2027
TABLE 58: Japan Current & Future Analysis for Clostridium Diagnostics by End-Use - Hospitals, Independent Laboratories and Physicians Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 59: Japan Historic Review for Clostridium Diagnostics by End-Use - Hospitals, Independent Laboratories and Physicians Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 60: Japan 15-Year Perspective for Clostridium Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Independent Laboratories and Physicians Clinics for the Years 2012, 2020 & 2027
CHINA
TABLE 61: China Current & Future Analysis for Clostridium Diagnostics by Technology - Immunoassays and Molecular Diagnostics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 62: China Historic Review for Clostridium Diagnostics by Technology - Immunoassays and Molecular Diagnostics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 63: China 15-Year Perspective for Clostridium Diagnostics by Technology - Percentage Breakdown of Value Sales for Immunoassays and Molecular Diagnostics for the Years 2012, 2020 & 2027
TABLE 64: China Current & Future Analysis for Clostridium Diagnostics by Bacterial Strain - Clostridium difficile, Clostridium perfringens, Clostridium botulinum, Clostridium tetani and Clostridium sordellii - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 65: China Historic Review for Clostridium Diagnostics by Bacterial Strain - Clostridium difficile, Clostridium perfringens, Clostridium botulinum, Clostridium tetani and Clostridium sordellii Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 66: China 15-Year Perspective for Clostridium Diagnostics by Bacterial Strain - Percentage Breakdown of Value Sales for Clostridium difficile, Clostridium perfringens, Clostridium botulinum, Clostridium tetani and Clostridium sordellii for the Years 2012, 2020 & 2027
TABLE 67: China Current & Future Analysis for Clostridium Diagnostics by End-Use - Hospitals, Independent Laboratories and Physicians Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 68: China Historic Review for Clostridium Diagnostics by End-Use - Hospitals, Independent Laboratories and Physicians Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 69: China 15-Year Perspective for Clostridium Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Independent Laboratories and Physicians Clinics for the Years 2012, 2020 & 2027
EUROPE
TABLE 70: Europe Current & Future Analysis for Clostridium Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR
TABLE 71: Europe Historic Review for Clostridium Diagnostics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 72: Europe 15-Year Perspective for Clostridium Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2012, 2020 & 2027
TABLE 73: Europe Current & Future Analysis for Clostridium Diagnostics by Technology - Immunoassays and Molecular Diagnostics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 74: Europe Historic Review for Clostridium Diagnostics by Technology - Immunoassays and Molecular Diagnostics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 75: Europe 15-Year Perspective for Clostridium Diagnostics by Technology - Percentage Breakdown of Value Sales for Immunoassays and Molecular Diagnostics for the Years 2012, 2020 & 2027
TABLE 76: Europe Current & Future Analysis for Clostridium Diagnostics by Bacterial Strain - Clostridium difficile, Clostridium perfringens, Clostridium botulinum, Clostridium tetani and Clostridium sordellii - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 77: Europe Historic Review for Clostridium Diagnostics by Bacterial Strain - Clostridium difficile, Clostridium perfringens, Clostridium botulinum, Clostridium tetani and Clostridium sordellii Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 78: Europe 15-Year Perspective for Clostridium Diagnostics by Bacterial Strain - Percentage Breakdown of Value Sales for Clostridium difficile, Clostridium perfringens, Clostridium botulinum, Clostridium tetani and Clostridium sordellii for the Years 2012, 2020 & 2027
TABLE 79: Europe Current & Future Analysis for Clostridium Diagnostics by End-Use - Hospitals, Independent Laboratories and Physicians Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 80: Europe Historic Review for Clostridium Diagnostics by End-Use - Hospitals, Independent Laboratories and Physicians Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 81: Europe 15-Year Perspective for Clostridium Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Independent Laboratories and Physicians Clinics for the Years 2012, 2020 & 2027
FRANCE
TABLE 82: France Current & Future Analysis for Clostridium Diagnostics by Technology - Immunoassays and Molecular Diagnostics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 83: France Historic Review for Clostridium Diagnostics by Technology - Immunoassays and Molecular Diagnostics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 84: France 15-Year Perspective for Clostridium Diagnostics by Technology - Percentage Breakdown of Value Sales for Immunoassays and Molecular Diagnostics for the Years 2012, 2020 & 2027
TABLE 85: France Current & Future Analysis for Clostridium Diagnostics by Bacterial Strain - Clostridium difficile, Clostridium perfringens, Clostridium botulinum, Clostridium tetani and Clostridium sordellii - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 86: France Historic Review for Clostridium Diagnostics by Bacterial Strain - Clostridium difficile, Clostridium perfringens, Clostridium botulinum, Clostridium tetani and Clostridium sordellii Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 87: France 15-Year Perspective for Clostridium Diagnostics by Bacterial Strain - Percentage Breakdown of Value Sales for Clostridium difficile, Clostridium perfringens, Clostridium botulinum, Clostridium tetani and Clostridium sordellii for the Years 2012, 2020 & 2027
TABLE 88: France Current & Future Analysis for Clostridium Diagnostics by End-Use - Hospitals, Independent Laboratories and Physicians Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 89: France Historic Review for Clostridium Diagnostics by End-Use - Hospitals, Independent Laboratories and Physicians Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 90: France 15-Year Perspective for Clostridium Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Independent Laboratories and Physicians Clinics for the Years 2012, 2020 & 2027
GERMANY
TABLE 91: Germany Current & Future Analysis for Clostridium Diagnostics by Technology - Immunoassays and Molecular Diagnostics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 92: Germany Historic Review for Clostridium Diagnostics by Technology - Immunoassays and Molecular Diagnostics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 93: Germany 15-Year Perspective for Clostridium Diagnostics by Technology - Percentage Breakdown of Value Sales for Immunoassays and Molecular Diagnostics for the Years 2012, 2020 & 2027
TABLE 94: Germany Current & Future Analysis for Clostridium Diagnostics by Bacterial Strain - Clostridium difficile, Clostridium perfringens, Clostridium botulinum, Clostridium tetani and Clostridium sordellii - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 95: Germany Historic Review for Clostridium Diagnostics by Bacterial Strain - Clostridium difficile, Clostridium perfringens, Clostridium botulinum, Clostridium tetani and Clostridium sordellii Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 96: Germany 15-Year Perspective for Clostridium Diagnostics by Bacterial Strain - Percentage Breakdown of Value Sales for Clostridium difficile, Clostridium perfringens, Clostridium botulinum, Clostridium tetani and Clostridium sordellii for the Years 2012, 2020 & 2027
TABLE 97: Germany Current & Future Analysis for Clostridium Diagnostics by End-Use - Hospitals, Independent Laboratories and Physicians Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR
TABLE 98: Germany Historic Review for Clostridium Diagnostics by End-Use - Hospitals, Independent Laboratories and Physicians Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR
TABLE 99: Germany 15-Year Perspective for Clostridium Diagnostics by End-Use - Percentage Breakdown of Value Sales for Hospitals, Independent Laboratories and Physicians Clinics for the Years 2012, 2020 & 2027
ITALY
TABLE 100: Italy Current & Future Analysis for Clostridium Diagnostics by Technology - Immunoassays and Molecular Diagnostics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook